Although the effectiveness of clozapine (CLZ) for patients with treatment-resistant schizophrenia (TRS) has been well established, its active mechanism has not been completely clarified. Several clinical studies showed that neuroleptic-induced dopamine supersensitivity psychosis (DSP) could be involved in the etiology of TRS. We preliminarily explored the possible beneficial effect of CLZ for dopamine supersensitivity schizophrenia. The present study is a case series. We followed 15 patients with DSP for about 2.5 years from the introduction of CLZ and compared the prevalence of episodes (particularly, rebound psychosis, tolerance to antipsychotic effects, or tardive dyskinesia) between the period before and during CLZ treatment. Our observation over 2.5 years following the introduction of CLZ showed that 13 of the 15 DSP patients presented no further DSP episodes. One patient showed continued tardive dyskinesia, which had already existed in the preperiod, and the other patient presented with rebound psychosis that appeared immediately after discontinuation of CLZ. The results of the present study indicated that DSP in schizophrenic patients treated with general antipsychotics disappeared over the subsequent 2.5 years under CLZ treatment, suggesting that the agent ameliorates the dopamine supersensitivity state induced by previous antipsychotic treatment.

中文翻译：

---

氯氮平对精神分裂症多巴胺超敏性精神病的疗效。

尽管氯氮平（CLZ）对耐药性精神分裂症（TRS）患者的疗效已得到公认，但其活性机制尚未完全阐明。多项临床研究表明，抗精神病药诱发的多巴胺超敏性精神病（DSP）可能与TRS的病因有关。我们初步探讨了CLZ对多巴胺超敏性精神分裂症的可能有益作用。本研究是一个案例系列。自从CLZ引入以来，我们对15例DSP患者进行了大约2.5年的随访，并比较了CLZ治疗之前和治疗期间的发作率（尤其是反弹性精神病，对抗精神病药的耐受性或迟发性运动障碍）。我们对2.的观察 引入CLZ后的5年表明，在15名DSP患者中，有13名没有出现进一步的DSP发作。一名患者表现出持续的迟发性运动障碍，这已经存在于早发期，另一名患者出现了反弹性精神病，在停药后立即出现反弹性精神病。本研究的结果表明，在普通抗精神病药治疗的精神分裂症患者中，在CLZ治疗后的2.5年内，DSP消失了，这表明该药可改善先前抗精神病药诱导的多巴胺超敏状态。